[ad_1]
Entry 2020.12.23 10:50
Modena also says: “Vaccines, variant corona check”
The British AstraZeneca reveals that “it will have a preventive effect on a crown variant and will prove its effectiveness”
The mutant virus, named ‘B.1.1.7 (VUI-202012/01)’, which has recently spread in the UK, has a maximum infectivity of up to 70% and is known to be easily transmitted to children.
Bioentech, a German pharmaceutical company that co-developed the Corona 19 vaccine with Pfizer in the United States, has tested 20 effects on the corona variant and, technically, it is a position that a new vaccine can be provided in 6 weeks.
Ugur Sahin (CEO) of Bioentech said that the company’s vaccine that uses “messenger ribonucleic acid” (mRNA, messenger RNA) will be able to cope with the crown variant. For an accurate diagnosis, research and information gathering is required for two weeks. He said it would come true. “Our vaccine contains more than 1,270 amino acids, and only 9 of them have changed in the variant crown,” said CEO Sahin. “This means that 99% of the protein remains the same.”
Pfizer has also begun to verify the efficacy of the vaccine against the variant of the virus. Pfizer made a statement and said it is collecting data by collecting blood samples from people with corona immunity to respond to the vaccine’s immune response against the variant of the virus.
German Curebag, who developed the Corona 19 vaccine with Modena in the United States, also said he believes it will be effective against the variant of the coronavirus that has spread in the United Kingdom. CureVac, which began phase 3 clinical trials last week, said it continues to see viral mutations, which is a common thing when the virus spreads.
The mRNA technology was also applied to the vaccine developed by Modena and Curebag. The AstraZeneca vaccine was developed on a more traditional basis, using adenovirus, a weak cold virus. The vaccines developed by Patrick Balances, the UK government’s chief scientific adviser, predicted that they could adequately trigger an immune response against the crown strain.
As a result, at least four global pharmaceutical companies have stated that their Corona 19 vaccine will be effective in preventing the newly discovered corona variant.
British pharmaceutical company AstraZeneca said: “The AZD1222 developed contains the genetic material of the protein peak that is prominent in the coronavirus. It appears that the change in the genetic code found in this variant did not change the structure of the protein peak.” “With AZD1222, the body’s immune system is trained to recognize different parts of the protein spike,” he said. “This is a way to get rid of it later when exposed to the virus.” AstraZeneca, which developed the Corona 19 vaccine in partnership with researchers at the University of Oxford in the UK, announced earlier this month that its vaccine prevention effect was 62-90%. He added that he has begun a study on the efficacy of his vaccine against this strain of virus.
The UK Department of Public Health believes the new strain is spreading faster than expected. New strains in the UK accounted for 28% of all new infections in early November, and on the 9th, they rose to one point to account for 62% of all COVID-19 infections. It was found that this strain can increase the reproductive rate of the infection by up to 0.4, which is an indicator of how many people can transmit the disease to a confirmed person.
